aa-P(=O)R1R2or a salt of the phosphine oxide compound. In the formula, R1and R2aa is a group having an unsaturated double bond, an epoxidized group, a hydroxylated group, or a phosphorus-containing group. The aryl groups of R1and R2 each have one to three substituents.
C07F 9/53 - Oxydes des organo-phospinesSulfures des organo-phosphines
C07F 9/655 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes d'oxygène, avec ou sans atomes de soufre, de sélénium ou de tellure, comme uniques hétéro-atomes du cycle
C08F 30/02 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant du phosphore
C08G 59/20 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les composés époxydés utilisés
The purpose of the present invention is to provide a novel organophosphorus compound. Provided is a dibenzophosphole oxide derivative represented by the following formula (where R1's are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic group, a substituted or unsubstituted non-aryl heterocyclic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group). A monomer of a dibenzophosphole oxide derivative containing a polymerizable group is produced, and a polymer thereof is prepared. The polymer has been found to have excellent electrical characteristics.
C07F 9/6568 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore comme uniques hétéro-atomes du cycle
C08F 20/30 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle contenant des cycles aromatiques dans la partie alcool
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
KATAYAMA CHEMICAL INDUSTRIES CO., LTD. (Japon)
Inventeur(s)
Han Li-Biao
Shinohara Hiroyuki
Mino Yuka
Kitamura Yuto
Fujino Hiroyoshi
Ikawa Eiichi
Mukai Takeshi
Abrégé
The present invention provides a method for producing an organophosphorus compound. A method for producing R1R2PONa, which comprises a step for reacting R1R2R3P(O) and sodium metal with each other, and which excludes the cases where a liquid ammonia is used as a solvent in the reaction, provided that each of R1, R2and R3 independently represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group. Consequently, the present invention provides a novel method for producing an organophosphorus compound. A production method according to the present invention is a safe and inexpensive method since a liquid ammonia is not used as a solvent and a low temperature is not required therefor. According to the present invention, by-products are suppressed in comparison to conventional methods, and a desired reaction proceeds highly selectively. In addition, a desired product is able to be synthesized in a single pot without requiring isolation.
Provided is a novel phosphorus compound. A compound represented by general formula (I) or a salt thereof. (In the formula, each of R1 and R2 independently represents a substituted or unsubstituted aryl group; each of R3 and R4 independently represents a hydrogen atom, or a substituted or unsubstituted alkyl group; n represents an integer of 1 or more, and in cases where n is 2 or more, the R3 moieties may be the same as or different from each other, and the R4 moieties may be the same as or different from each other; and R5 represents a hydrogen atom, or a substituted or unsubstituted alkyl group.)
C07F 9/53 - Oxydes des organo-phospinesSulfures des organo-phosphines
C08F 30/02 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant du phosphore
C09K 3/18 - Substances non couvertes ailleurs à appliquer sur des surfaces pour y minimiser l'adhérence de la glace, du brouillard ou de l'eauSubstances antigel ou provoquant le dégel pour application sur des surfaces
C09K 21/12 - Substances organiques contenant du phosphore
The present invention provides a simple addition reaction of a phosphorus compound with respect to an alkene. The present invention provides a production method in which an alkene and a phosphorus compound are reacted in the presence of a catalytic amount of a base to enable the synthesis of simple addition products including novel compounds that are compatible with various substrates and are considered to have high utility. The advantages of the present production method over conventional production methods are as follows: (1) the residual halogen components and residual metal components in the product are decreased; (2) a compound with completely controlled regioselectivity is obtained, i.e., the target is 100% generated; and (3) production costs can be reduced.
Provided is a method for producing an alkenyl phosphorus compound that can efficiently produce the alkenyl phosphorus compound even when using a smaller amount of catalyst than prior methods, can produce the alkenyl phosphorus compound with high yield while maintaining catalytic activity even at a larger reaction scale, and can be employed even in large-scale synthesis on an industrial scale using conventional batch reactors or continuous reactors. A method for producing an alkenyl phosphorus compound represented by formula (3a) and/or formula (3b) (in formulas (3a) and (3b), R1 and R2 are as defined in formula (1), and R5 is as defined in formula (2)) that includes a step for reacting the compound represented by formula (1) (in formula (1), R1 represents OR3 or R3, R2 represents OR4 or R4, and R3 and R4 independently represent a substituted or unsubstituted alkyl group or the like) and the compound represented by formula (2) (in formula (2), R5 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like), the method being characterized by using a transition metal catalyst and an oxo acid compound of phosphorus having a P-H bond in the molecule to react the compound represented by formula (1) and the compound represented by formula (2).
Provided is a chemical reaction which omits or simplifies treatment after reaction. This problem is solved by a method for producing a product by a chemical reaction which comprises: (A) a step of producing a product by reacting a substance to be used for the chemical reaction in a solvent under conditions in which the product is produced, the solvent having a solubility such that the product and at least one substance of the substance used for the chemical reaction and a byproduct generated from the chemical reaction are present in substantially different phases out of a dissolved phase and a non-dissolved phase, with respect to the product and the at least one substance; and (B) a step of taking out the product from the reaction system of the chemical reaction.
C07C 231/08 - Préparation d'amides d'acides carboxyliques à partir d'amides par réaction sur les atomes d'azote de groupes carboxamide
C07C 233/26 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome de carbone acyclique d'un squelette carboné saturé contenant des cycles
The present invention provides a flame retardant that can be used as a polymer, or a novel material that can be used as a raw material for a flame retardant. In particular, the present invention provides a compound represented by formula (A). In the formula, Ra and Rb are each independently a substituent such as hydrogen, an aryl group, a substituted aryl group, or an alkyl group, or Ra and Rb together form an additional cyclic skeleton; R1 and R2 are each independently the same or different radical polymerizable groups; and R3, R4, and R5 are each independently a substituent such as a hydrogen atom, a halogen atom, an alkyl group, or a substituted alkyl group.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
KATAYAMA CHEMICAL INDUSTRIES CO.,LTD. (Japon)
Inventeur(s)
Han, Li-Biao
Futamura, Seiji
Fujino, Hiroyoshi
Watanabe, Tomoko
Abrégé
Provided are alkenylphosphorus compound polymers and alkenylphosphorus compound copolymers which overcome the problems associated with conventional flame retardants, and which also exhibit a characteristic of being rarely discolored even when heated. Also provided are alkenylphosphorus compounds suitable as starting monomers for the polymers and copolymers. The akenylphosphorus compound polymers are represented by general formula (2). The alkenylphosphorus compound copolymers are copolymers obtained by copolymerizing an alkenylphosphorus compound represented by general formula (1) with an alkene compound represented by general formula (3).
C08F 30/02 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant du phosphore
Provided is a therapeutic agent containing an ammine-platinum complex (particularly cisplatin) which has less side effects and specifically acts on tumor or cancer; and a method using the same. Also provided is a composition for treating cancer or tumor. This composition contains cis-diamminedichloroplatinum (II), and liposome contains a target-directed substance on the surface thereof. In one embodiment, the target-directed substance is selected from the group consisting of antibodies and sugar chains. In a preferred embodiment, the target-directed substance is sialyl Lewis-X or anti-E-selectin antibody. In one embodiment, the cancer or tumor is selected from the group consisting of colon cancer, lung cancer, squamous cell carcinoma, breast cancer and ovarian cancer.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Disclosed is a liposome containing a metal colloid in a large quantity. Also disclosed is a method for producing a liposome containing a metal colloid. Further disclosed are an imaging agent and a composition each of which comprises a liposome containing a metal colloid. The liposome may contain iron (Fe), gadolinium (Gd), gold (Au), europium (Eu) or the like as the metal. The liposome may additionally contain a target-directing substance.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
Provided are glycolipid-containing liposomes. In the glycolipid-containing liposomes, said glycolipids comprise plant ceramide portions and sugar chain portions. Also provided is a method for manufacturing glycolipid-containing liposomes. This method comprises the following: A) a process that provides a glycolipid, whereby said glycolipid comprises plant ceramide portions and sugar chain portions, and B) a process that mixes said provided glycolipid and a liposome starting material and subjects them to conditions in which liposomes are formed.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p. ex. acide clodronique, acide pamidronique
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
National University Corporation Okayama University (Japon)
Inventeur(s)
Hirohata, Satoshi
Ogawa, Hiroko
Kusachi, Shozo
Ninomiya, Yoshifumi
Hatanaka, Kunihiko
Igarashi, Koichi
Abrégé
Disclosed is a pharmaceutical composition which is effective for the treatment/prevention, detection or diagnosis of arteriosclerosis. In one aspect, disclosed is a pharmaceutical composition for the diagnosis, treatment or prevention of a lesion of arteriosclerosis, which comprises a hydrophilized liposome and a factor specific to the lesion of arteriosclerosis. Also disclosed is a diagnostic composition for the diagnosis of a lesion of arteriosclerosis. The diagnostic composition comprises A) a hydrophilized liposome, B) a factor specific to the lesion of arteriosclerosis, and C) a labeling substance.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
14.
MEDICINE AND MEDICAL INSTRUMENT CONTAINING OSTEOGENIC AND CHONDROGENIC PROTEIN
It is intended to provide a medicine capable of acting exclusively in a site where an osteoblast is present and quickly inducing osteogenesis associated with chondrogenesis in the same manner as in natural healing without causing a side effect such as serious inflammation in vivo. The above problem has been solved by providing a bone therapeutic agent which contains NELL1 for treating bone without causing inflammation. The bone therapeutic agent as described above is usable for repairing bone defect after lesion curettage or excision, prolonging bone fracture healing, pseudo-joint formation, distraction osteogenesis, artificial joint replacement, spinal fusion, cartilage transplantation, transplantation into jaw cleft, repairing bone defect caused by wound, repairing bone defect after craniotomy, alveolar ridge formation, maxillary sinus floor lifting, alveolar bone regeneration, jaw bone regeneration around artificial dental root, and so on.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
15.
CATALYST FOR PHOSPHORUS-CONTAINING COMPOUND AND SULFUR-CONTAINING COMPOUND
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Han, Li-Biao
Fujino, Hiroyoshi
Saga, Yuta
Kitagaki, Kouji
Hasegawa, Kaoru
Abrégé
This invention provides a process for producing an alkenylphosphorus compound using a hydrogenated phosphonic acid ester, a hydrogenated phosphinic acid ester, or a disubstituted phosphine oxide as a starting compound in the presence of an inexpensive catalyst. A complex compound represented by [HNi(PR1R2R3)2]+X- or [HNi(R1R2P(CH2)XPR4R5)]+X- wherein R1, R2, R3, R4, and R5 each independently represent a substituted or unsubstituted hydrocarbon group; X represents an anion of an acid as a hydride donor (for example, an inorganic acid or an organic acid); and x is a positive integer.
JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (Japon)
Inventeur(s)
Wakita, Hideaki
Igarashi, Koichi
Oie, Kazunori
Abrégé
The invention provides a pharmaceutical composition for treating or preventing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system containing a liposome, and sialyl Lewis X (SLX) or an SLX group. The invention also provides a diagnostic composition for diagnosing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system. This diagnostic composition contains A) a liposome, B) sialyl Lewis X (SLX) or an SLX group, and C) a labeling substance. The invention also provides a method for treating or preventing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system. The invention also provides a method for detecting an ischemic site in the central nervous system. The invention also provides use of SLX in production of a pharmaceutical for treating, preventing, detecting, or diagnosing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system. The invention also provides a delivery medium for delivering a target substance to the inside of cells.
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7012 - Composés ayant un groupe carboxyle libre ou estérifié, lié directement ou par une chaîne carbonée, à un atome de carbone du radical saccharide, p. ex. acide glucuronique, acide neuraminique
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
Disclosed is an antibody-modified liposome. The antibody-modified liposome may comprise: (A) a liposome; (B) serum albumin bound to the liposome; (C) a spacer bound to serum albumin present on the surface of the liposome; and (D) an antibody bound to the spacer. Also disclosed are: a method for producing the antibody-modified liposome; and use of the antibody-modified liposome. Further disclosed are: a composition and a diagnosis method for diagnosing cancer or tumor; and a molecular imaging agent.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
18.
LIPOSOME ENCAPSULATING AMMINE-PLATINUM COMPLEX AT HIGH CONCENTRATION, AND METHOD FOR PRODUCTION OF THE LIPOSOME
Disclosed is a method for producing a liposome encapsulating an ammine-platinum complex. The method comprises the steps of: A) providing a water-soluble ammine-platinum complex, a platinum complex raw material or a combination thereof; B) providing a liposome, a liposome raw material or a combination thereof; and C) preparing a mixture of the water-soluble ammine-platinum complex, the platinum complex raw material or the combination thereof and the liposome, the liposome raw material or the combination thereof and subjecting the mixture under the conditions where a liposome can be formed and maintained, wherein a salt formed by the platinum complex is in a water-soluble form at the time point where the liposome exists.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
KATAYAMA CHEMICAL INDUSTRIES CO., LTD. (Japon)
Inventeur(s)
Yamazaki, Noboru
Oie, Kazunori
Abrégé
It is intended to provide a molecular imaging agent. Namely, there is provided a sugar chain-modified liposome comprising a liposome, a sugar chain group, a linker protein group and a hydrophilic compound group, wherein the linker protein group attaches to the outer face of the liposome, the sugar chain group attaches to at least a part of the linker protein group, and the hydrophilic compound group attaches to the outer face of the liposome or a part of the linker protein group. In another aspect, a medicinal composition which comprises the sugar chain-modified liposome together with a pharmaceutically active ingredient is provided. In a still another aspect, a sugar chain-modified liposome to be used as a molecular imaging agent is provided. In a still another aspect, a method of producing a liposome containing a labeled sugar chain is provided.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
brevets